非酒精性脂肪性肝病肝纤维化的诊断和治疗进展

朱红梅; 王勤英

doi:10.3969/j.issn.1001-5256.2020.01.042

非酒精性脂肪性肝病肝纤维化的诊断和治疗进展

DOI: 10.3969/j.issn.1001-5256.2020.01.042

1. 山西医科大学
2. 山西医科大学第一医院感染科

详细信息

中图分类号: R575.5;R575.2
计量
- 文章访问数: 1133
- HTML全文浏览量: 32
- PDF下载量: 295
- 被引次数: 0
出版历程
- 收稿日期: 2019-09-02
- 出版日期: 2020-01-20

Advances in the diagnosis and treatment of nonalcoholic fatty liver disease-related liver fibrosis

Shanxi Medical University

摘要

摘要: 非酒精性脂肪性肝病(NAFLD)正成为全球最常见的慢性肝病。从其疾病谱来看,非酒精性脂肪性肝炎(NASH)是疾病进展形式,可进展为肝纤维化,从而导致NAFLD相关肝硬化和肝癌。NASH肝纤维化与疾病预后密切相关,临床亟需有效措施诊断及干预疾病进展。重点介绍了目前非酒精性脂肪性肝纤维化的诊断和治疗进展。
- 非酒精性脂肪性肝病 /
- 肝硬化 /
- 诊断 /
- 治疗学
Abstract: Nonalcoholic fatty liver disease(NAFLD) is becoming the most common chronic liver disease in the world. From the perspective of its disease spectrum,nonalcoholic steatohepatitis(NASH) is a form of disease progression and can progress to liver fibrosis,leading to NAFLD-related liver cirrhosis and liver cancer. NASH-related liver fibrosis is closely associated with prognosis,and effective measures are urgently needed for the diagnosis and intervention of disease progression. This article summarizes the research advances in the diagnosis and treatment of NAFLD-related liver fibrosis.
- non-alcoholic fatty liver disease /
- liver cirrhosis /
- diagnosis /
- therapeutics

HTML全文

参考文献(38)

[1] WANG ZT,HU RH,XIONG Y. Progressoftreatmentonnon-alcoholicfattyliverdisease[J/CD]. Chin J Liver Dis(Electr Version),2018,10(4):48-53.(in Chinese)王中涛，胡荣华，熊勇．非酒精性脂肪性肝病治疗进展[J/CD]．中国肝脏病杂志(电子版)，2018,10(4):48-53.

[2] POVSIC M,WONG OY,PERRY R et al. A structured literature review of the epidemiology and disease burden of nonalcoholic steatohepatitis(NASH)[J]. Adv Ther,2019,36(42):1574-1594.

[3] BERG EHVD,DOUWES RM,MEIJER VED,et al. Liver transplantation for NASH cirrhosis is not performed at the expense of major post-operative morbidity[J]. Dig Liver Dis,2018,50(1):68-75.

[4] LEI H,LINFENG D,QUAN Z,et al. Diagnostic value of CK-18,FGF-21,and related biomarker panel in nonalcoholic fatty liver disease:A systematic review and meta-analysis[J].Bio Med Res Int,2017,2017:1-12.

[5] SUZUKI A,ANGULO P,LYMP J,et al. Hyaluronic acid,an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease[J]. Liver Int,2010,25(4):779-786.

[6] WANG XX,LI XH,LIU F,et al. Progress in serum markers for non-alcoholic fatty liver disease[J]. Chin J Lab Med,2019,42(3):165-169.(in Chinese)王晓晓，李晓鹤，刘峰，等．非酒精性脂肪性肝病血清学检测进展[J]．中华检验医学杂志，2019,42(3):165-169.

[7] XIAO G,ZHU S,XIAO X,et al. Comparison of laboratory tests,ultrasound,or MRE to detect fibrosis in patients with non-alcoholic fatty liver disease:A meta-analysis[J]. Hepatology,2017,66(5):1486-1501.

[8] ANGULO P,HUI JM,MARCHESINI G,et al. The NAFLD fibrosis score:A noninvasive system that identifies liver fibrosis in patients with NAFLD[J]. Hepatology,2007,45(4):846-854.

[9] MCPHERSON S,STEWART SF,HENDERSON E,et al. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease[J]. Gut,2010,59(9):1265-1269.

[10] MCPHERSON S,HARDY T,DUFOUR JF,et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis[J]. Am J Gastroenterol,2017,112(5):740-751.

[11] GUHA IN,PARKES J,RODERICK P,et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease:Validating the european liver fibrosis panel and exploring simple markers[J]. Hepatology,2008,47(2):455-460.

[12] BOURSIER J,DE LV,LEROY V,et al. A stepwise algorithm using an at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis[J]. J Hepatol,2017,66(6):1158-1165.

[13] TAPPER EB,CHALLIES T,NASSER I,et al. The performance of vibration controlled transient elastography in a US cohort of patients with nonalcoholic fatty liver disease[J]. Am J Gastroenterol,2016,111(5):677-684.

[14] CHALASANI N,YOUNOSSI Z,LAVINE JE,et al. The diagnosis and management of nonalcoholic fatty liver disease:Practice guidance from the American Association for the Study of Liver Diseases[J]. Hepatology,2018,67(1):328-357.

[15] HONG J,SHI YW,WU XN,et al. Application value of imaging diagnosis in nonalcoholic fatty liver disease[J]. J Clin Hepatol,2018,34(12):2698-2701.(in Chinese)洪佳，施漪雯，吴晓宁，等．影像学诊断技术在非酒精性脂肪性肝病中的应用价值[J]．临床肝胆病杂志，2018,34(12):2698-2701.

[16] LIU H,FU J,HONG R,et al. Acoustic radiation force impulse elastography for the non-invasive evaluation of hepatic fibrosis in non-alcoholic fatty liver disease patients:A systematic review&meta-analysis[J]. PLo S One,2015,10(7):e0127782.

[17] CASSINOTTO C,JROME B,VICTOR DE L,et al. Liver stiffness in nonalcoholic fatty liver disease:A comparison of supersonic shear imaging,FibroScan,and ARFI with liver biopsy[J]. Hepatology,2016,63(6):1817-1827.

[18] FLORES A,ASRANI SK. Editorial:Magnetic resonance elastography and non-alcoholic fatty liver disease:Time for an upgrade?[J]. Am J Gastroenterol,2016,111(7):995-996.

[19] BESUTTI G,VALENTI L,LIGABUE G,et al. Accuracy of imaging methods for steatohepatitis diagnosis in non-alcoholic fatty liver disease patients:A systematic review[J]. Liver Int,2019,39(8):1521-1534.

[20] HANG SX,SHEN HY,CHEN M. Correlation of serum SHGB levels with insulin sensitivity,lipid metabolism,oxidative stress in patients with nonalcoholic fatty liver disease[J]. J Clin Exp Med,2019,18(1):82-85.(in Chinese)杭双熊，申红玉，陈敏．非酒精性脂肪性肝病患者血清SHGB含量与胰岛素敏感性、脂代谢、氧化应激的相关性[J]．临床和实验医学杂志，2019,18(1):82-85.

[21] VILAR-GOMEZ E,YASELLS-GARCIA A,MARTINEZ-PEREZ Y,et al. Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention[J]. Hepatology,2016,63(6):1875-1887.

[22] TANNAZ E,PUNEETA T,MAITREYI R. Dietary composition independent of weight loss in the management of non-alcoholic fatty liver disease[J]. Nutrients,2017,9(8):800.

[23] ROEB E,STEFFEN HM,BANTEL H,et al. S2k Guideline non-alcoholic fatty liver disease[J]. Z Gastroenterol,2015,53(7):668-723.

[24] PACANA T,SANYAL AJ. Vitamin E and nonalcoholic fatty liver disease[J]. Curr Opin Clin Nutr Metab Care,2012,15(6):641-648.

[25] GOLABI P,BUSH H,YOUNOSSI ZM. Treatment strategies for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis[J]. Clin Liver Dis,2017,21(4):739-753.

[26] ZEIN CO,YERIAN LM,GOGATE P,et al. Pentoxifylline improves nonalcoholic steatohepatitis:A randomized placebocontrolled trial[J]. Hepatology,2011,54(5):1610-1619.

[27] LOOMBA R,LAWITZ E,MANTRY PS,et al. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis:A randomized,phase 2 trial[J]. Hepatology,2017,67(2):549-559.

[28] RATZIU V,HARRISON SA,FRANCQUE S,et al. Elafibranor,an agonist of the peroxisome proliferator-activated receptor-αand-δ，induces resolution of nonalcoholic steatohepatitis without fibrosis worsening[J]. Gastroenterology,2016,150(5):1147-1159. e5.

[29] PAI V,PANEERSEIVAM A,MUKHOPADHYAY S,et al. A Multicenter,prospective,randomized,double-blind study to evaluate the safety and efficacy of saroglitazar 2 and 4 mg compared to pioglitazone 45 mg in diabetic dyslipidemia(PRESS V)[J]. J Diabetes Sci Technol,2014,8(1):132-141.

[30] ARMSTRONG MJ,GAUNT P,AITHAL GP,et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis(LEAN):A multicentre,double-blind,randomised,placebo-controlled phase 2 study[J]. Lancet,2016,387(10019):679-690.

[31] NEUSCHWANDERTETRI BA,LOOMBA R,SANYAL AJ,et al.Farnesoid X nuclear receptor ligand obeticholic acid for noncirrhotic,non-alcoholic steatohepatitis(FLINT):A multicentre,randomised,placebo-controlled trial[J]. Lancet,2015,385(9972):956-965.

[32] HARRISON SA,RINELLA ME,ABDELMALEK MF,et al. NGM282for treatment of non-alcoholic steatohepatitis:A multicentre,randomised,double-blind,placebo-controlled,phase 2 trial[J].Lancet,2018,391(10126):1174-1185.

[33] LAWITZ EJ,COSTE A,POORDAD F,et al. Acetyl-Co A carboxylase inhibitor GS-0976 for 12 weeks reduces hepatic de novo lipogenesis and steatosis in patients with nonalcoholic steatohepatitis[J]. Clin Gastroenterol Hepatol, 2018, 16(12):1983-1991.

[34] JIA H,RAO HY. Clinical trials tracking nonalcoholic fatty liver disease:Drug classification[J]. J Clin Hepatol,2018,34(12):2495-2500.(in Chinese)贾寒，饶慧瑛．跟踪非酒精性脂肪性肝病的临床试验-药物分类[J]．临床肝胆病杂志，2018,34(12):2495-2500.

[35] FRIEDMAN S,SANYAL A,GOODMAN Z,et al. Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis:CENTAUR Phase 2b study design[J]. Contemp Clin Trials,2016,47:356-365.

[36] HE WW,AN XF,LI L,et al. Relationship between hypothyroidism and non-alcoholic fatty liver disease:A systematic review and Meta-analysis[J]. Front Endocrinol(Lausanne),2017,8:335.

[37] SAYINER M,LAM B,GOLABI P,et al. Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis[J]. Ther Adv Gastroenterol,2018,11:1-12.

[38] HUNG CK,BODENHEIMER HC. Current treatment of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis[J]. Clin Liver Dis,2018,22(1):175-187.

施引文献

资源附件(0)

访问统计